ClinicalTrials.gg
CompletedNCT01278134Updated Nov 2, 2016

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

A Phase 2 interventional study of Copegus placebo and RO5024048 in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 32 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
34th of 83
170 · median 129
Started
2011
with 6 others
Phase 2
10 of 83
none open now
Registered
58th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 34th largest by enrollment, is one of 7 that started in 2011, is one of 10 in phase 2, and was the 58th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This multicenter, randomized, double-blind, parallel group study will evaluate the safety and efficacy of the combination RO5024048 and ritonavir-boosted danoprevir with and without Copegus (ribavirin) in patients with chronic hepatitis C genotype 1. In arm A and B, interferon treatment-naïve patients will receive 1000 mg RO5024048 orally twice daily and 100 mg danoprevir with 100 mg ritonavir orally twice daily plus either Copegus (1000 mg or 1200 mg orally daily) or placebo for 12 weeks. Depending on viral response and treatment arm patients will be re-randomized to continue assigned treatment for additional 12 weeks or stop all treatment. The anticipated time on study treatment is up to 24 weeks plus a 24-week follow-up.

As of 29. September 2011, Arm B patients (placebo-containing arm) will be offered, in conjunction with the current treatment, Pegasys (peginterferon alfa-2a) 180 mcg subcutaneously weekly plus Copegus 1000mg or 1200 mg orally daily for 24 weeks, with a 24-week follow-up.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient, >/= 18 years of age
  • Chronic of >/= 6 months duration at screening
  • HCV genotype 1 and quantifiable HCV RNA at screening (Roche COBAS TaqMan HCV test)
  • Naïve for treatment with interferon (pegylated or non-pegylated)
  • (BMI) 18-35 inclusive, minimum weight 45 kg
  • Females of and males with female partners of childbearing potential must use 2 forms of effective non-hormonal

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women and males with female partners who are pregnant or lactating
  • Decompensated liver disease or impaired liver function
  • Cirrhosis or incomplete/transition to cirrhosis
  • Non- chronic liver disease
  • or infection
  • History of neoplastic disease within the last 5 years, except for localized or in situ carcinoma of the skin
  • History of pre-existing renal disease (except for nephrolithiasis) or severe cardiac disease
  • History of drug or alcohol abuse within the last year or alcohol consumption of > 2 units per day; cannabinoid use is excepted
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Arm B Extension

    All patients in treatment arm B were offered to receive Pegasys/Cogepus therapy for an additional 24 weeks.

    Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin [Copegus]

  • Experimental
    RO5024048 & ritonavir-boosted danoprevir without Ribavirin (B)

    Drug: Copegus placebo · Drug: RO5024048 · Drug: danoprevir · Drug: ritonavir

  • Experimental
    RO5024048 and ritonavir-boosted danoprevir with Ribavirin (A)

    Drug: RO5024048 · Drug: danoprevir · Drug: ribavirin [Copegus] · Drug: ritonavir

Interventions

  • DrugCopegus placebo

    1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks

  • 1000 mg bid orally, up to 24 weeks

  • 100 mg bid orally, up to 24 weeks

  • 180 mcg sc weekly, 24 weeks

  • 1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks

  • 100 mg bid orally, up to 24 weeks

06

What researchers measure

Primary outcomes

  1. Sustained virological response, defined as undetectable HVC RNA measured by Roche COBAS TaqMan HCV test

    Time frame: 24 weeks after end of treatment

  2. Safety: Incidence of adverse events

    Time frame: 1.5 years

Secondary outcomes

  1. Virological response (HCV RNA measured by Roche COBAS Taqman HCV test)

    Time frame: up to 48 weeks

  2. Impact of Copegus (ribavirin) on efficacy of the direct-acting antiviral combination regimen: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)

    Time frame: 1.5 years

  3. Comparison of 12 and 24 weeks of treatment duration: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)

    Time frame: 1.5 years

  4. Pharmacokinetics: Plasma concentrations of danoprevir, ritonavir, RO4995855 (parent drug of RO5024048) and ribavirin

    Time frame: up to 24 weeks

  5. Viral resistance: HCV RNA sequencing and phenotypic analyses

    Time frame: up to 48 weeks

  6. Effect of interleukin 28B genotype on efficacy: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)

    Time frame: 1.5 years

  7. Quality of life: SF-36 questionnaire, Fatigue Severity Scale

    Time frame: up to 36 weeks

07

Study locations

32 sites
  • La Jolla, California 92037-1030, United States
  • Sacramento, California 95817, United States
  • Orlando, Florida 32809, United States
  • Marietta, Georgia 30060, United States
  • Honolulu, Hawaii 96814, United States
  • Honolulu, Hawaii 96817, United States
  • Chicago, Illinois 60637, United States
  • Indianapolis, Indiana 46202, United States
  • Lutherville, Maryland 21093, United States
  • Detroit, Michigan 48202, United States
  • Newark, New Jersey 07102, United States
  • Albuquerque, New Mexico 87131, United States
  • New York, New York 10021, United States
  • Providence, Rhode Island 02905, United States
  • Nashville, Tennessee 37211, United States
  • Houston, Texas 77030, United States
  • Newport News, Virginia 23602, United States
  • Vancouver, Washington 98664, United States
  • Clichy, 92118, France
  • Creteil, 94010, France
  • Lille, 59037, France
  • Marseille, 13285, France
  • Montpellier, 34295, France
  • Paris, 75651, France
  • Berlin, 10969, Germany
  • Berlin, 13353, Germany
  • Frankfurt Am Main, 60590, Germany
  • Hamburg, 20099, Germany
  • Hannover, 30625, Germany
  • Kiel, 24146, Germany
  • Leipzig, 04103, Germany
  • Grafton, 1010, New Zealand
08

References and documents

Publications

  • Tong X, Li L, Haines K, Najera I. Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir. Antimicrob Agents Chemother. 2014 Jun;58(6):3105-14. doi: 10.1128/AAC.02672-13. Epub 2014 Mar 17. PubMed 24637689 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2011
First posted
Jan 17, 2011
Start
Feb 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results delay requested
Jul 20, 2016
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01278134
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 17, 2011
Start date
Feb 2011
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mericitabine · Peginterferon alfa-2a · Ribavirin

Start the discussion